期刊文献+

Expressions of Tissue Factor and Tissue Factor Pathway Inhibitor in Patients with Acute Graft-versus-host Disease after Allogeneic Hematopoietic Stem Cell Transplantation

Expressions of Tissue Factor and Tissue Factor Pathway Inhibitor in Patients with Acute Graft-versus-host Disease after Allogeneic Hematopoietic Stem Cell Transplantation
下载PDF
导出
摘要 This study examined the expressions of human serum tissue factor (TF) and tissue factor pathway inhibitor (TFPI) in patients with acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) and their clinical significance. The serum TF and TFPI levels were detected by ELISA in 28 allo-HSCT recipients before and after the transplanta-tion and the changes of TF and TFPI levels were dynamically monitored at different phases of the disease. No significant differences in the serum TF and TFPI levels were found in allo-HSCT recipi-ents in the absence of aGVHD or with gradeⅠaGVHD before and after the transplantation. The lev-els of serum TF and TFPI were substantially increased in the patients with gradeⅡ aGVHD at the peak of aGVHD (P〈0.05) and they were even higher in the patients with grade Ⅲ–Ⅳ aGVHD (P〈0.01). When the conditions became stable after treatment with immunosuppressive agents, the serum TFPI level was decreased to the baseline level (P〉0.05) and the TF level was lowered but still higher than the baseline level (P〈0.05). It was concluded that the levels of serum TF and TFPI were increased significantly in the patients with grade Ⅱ–Ⅳ aGVHD after allo-HSCT and decreased markedly after the treatment. Monitoring the levels of serum TF and TFPI in the patients with allo-HSCT is important to predict the occurrence, outcome and prognosis of aGVHD. This study examined the expressions of human serum tissue factor (TF) and tissue factor pathway inhibitor (TFPI) in patients with acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) and their clinical significance. The serum TF and TFPI levels were detected by ELISA in 28 allo-HSCT recipients before and after the transplanta-tion and the changes of TF and TFPI levels were dynamically monitored at different phases of the disease. No significant differences in the serum TF and TFPI levels were found in allo-HSCT recipi-ents in the absence of aGVHD or with gradeⅠaGVHD before and after the transplantation. The lev-els of serum TF and TFPI were substantially increased in the patients with gradeⅡ aGVHD at the peak of aGVHD (P〈0.05) and they were even higher in the patients with grade Ⅲ–Ⅳ aGVHD (P〈0.01). When the conditions became stable after treatment with immunosuppressive agents, the serum TFPI level was decreased to the baseline level (P〉0.05) and the TF level was lowered but still higher than the baseline level (P〈0.05). It was concluded that the levels of serum TF and TFPI were increased significantly in the patients with grade Ⅱ–Ⅳ aGVHD after allo-HSCT and decreased markedly after the treatment. Monitoring the levels of serum TF and TFPI in the patients with allo-HSCT is important to predict the occurrence, outcome and prognosis of aGVHD.
出处 《Journal of Huazhong University of Science and Technology(Medical Sciences)》 SCIE CAS 2009年第6期697-700,共4页 华中科技大学学报(医学英德文版)
关键词 hematopoietic stem cell transplantation graft-versus-host disease tissue factor tissue factor pathway inhibitor hematopoietic stem cell transplantation graft-versus-host disease tissue factor tissue factor pathway inhibitor
  • 相关文献

参考文献11

  • 1A. Sureda,N. Schmitz.Allogeneic stem cell transplantation after reduced-intensity conditioning in lymphoid malignancies[J].Annals of Hematology.2003(1)
  • 2Zhang ZL,Shen T.Blood disease diagnosis and efficacy standards[]..1999
  • 3Imamura T.Tissue factor expression at the site of in- flammation: a cross-talk between inflammation and the blood coagulation system[].Rinsho Byori.2004
  • 4Camerer E,Kolsto A B,Prydz H.Cell biology of tissue factor, the principal initiator of blood coagulation[].Thrombosis Research.1996
  • 5Carmeliet P,Mackman N,Moons L,et al.Role of tissue factor in embryonic blood vessel development[].Nature.1996
  • 6Shebuski RJ,Kilgore KS,et al.Role of inflammatory mediators in thrombogenesis[].Journal of Pharmacology and Experimental Therapeutics.2002
  • 7Levy MM,Fink MP,Marshall JC,et al.2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference[].Critical Care Medicine.2003
  • 8Gando S,Kameue T,Morimoto Y,et al.Tissue factor production not balanced by tissue factor pathway inhibitor in sepsis promotes poor prognosis[].Critical Care Medicine.2002
  • 9Enkhbaatar P,Okajima K,Murakami K,et al.Recombinant tissue factor pathway inhibitor reduces lipopolysaccharide-induced pulmonary vascular injury by inhibiting leukocyte activation[].American Journal of Respiratory and Critical Care Medicine.2000
  • 10Hansen J B,Svensson B,Olsen R,et al.Heparin induces synthesis and secretion of tissue factor pathway inhibitor from endothelial cells in vitro[].Thrombosis and Haemostosis.2000

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部